2022
Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment
Petersen G, Shatalov J, Verma T, Brim WR, Subramanian H, Brackett A, Bahar RC, Merkaj S, Zeevi T, Staib LH, Cui J, Omuro A, Bronen RA, Malhotra A, Aboian MS. Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment. American Journal Of Neuroradiology 2022, 43: 526-533. PMID: 35361577, PMCID: PMC8993193, DOI: 10.3174/ajnr.a7473.Peer-Reviewed Original ResearchMeSH KeywordsGliomaHumansLymphomaMachine LearningMagnetic Resonance ImagingReproducibility of ResultsConceptsMachine learning-based methodsLearning-based methodsBalanced data setData setsVector machine modelMachine learningClassification algorithmsMachine modelMachineAlgorithmData basesPrediction modelPromising resultsPrimary CNS lymphomaPrediction model study RiskRisk of biasRadiomic featuresClassifierSetCNS lymphomaWebLearningFeaturesQualitySystematic reviewUsing Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology
Joel MZ, Umrao S, Chang E, Choi R, Yang DX, Duncan JS, Omuro A, Herbst R, Krumholz HM, Aneja S. Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology. JCO Clinical Cancer Informatics 2022, 6: e2100170. PMID: 35271304, PMCID: PMC8932490, DOI: 10.1200/cci.21.00170.Peer-Reviewed Original ResearchMeSH KeywordsBreastDeep LearningHumansMagnetic Resonance ImagingMammographyTomography, X-Ray Computed
2021
Comparison of radiomic feature aggregation methods for patients with multiple tumors
Chang E, Joel MZ, Chang HY, Du J, Khanna O, Omuro A, Chiang V, Aneja S. Comparison of radiomic feature aggregation methods for patients with multiple tumors. Scientific Reports 2021, 11: 9758. PMID: 33963236, PMCID: PMC8105371, DOI: 10.1038/s41598-021-89114-6.Peer-Reviewed Original ResearchConceptsCox proportional hazards modelCox proportional hazardsProportional hazards modelBrain metastasesRadiomic featuresHazards modelProportional hazardsStandard Cox proportional hazards modelMultifocal brain metastasesMultiple brain metastasesNumber of patientsPatient-level outcomesHigher concordance indexRadiomic feature analysisRandom survival forest modelSurvival modelsDifferent tumor volumesMultifocal tumorsCancer outcomesMultiple tumorsMetastatic cancerConcordance indexTumor volumePatientsTumor types
2019
Imaging biomarkers for brain metastases: more than meets the eye
Aneja S, Omuro A. Imaging biomarkers for brain metastases: more than meets the eye. Neuro-Oncology 2019, 21: 1493-1494. PMID: 31777936, PMCID: PMC6917408, DOI: 10.1093/neuonc/noz193.Peer-Reviewed Original ResearchResidual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging
Thulborn KR, Lu A, Atkinson IC, Pauliah M, Beal K, Chan TA, Omuro A, Yamada J, Bradbury MS. Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. Clinical Cancer Research 2019, 25: 1226-1232. PMID: 30487127, PMCID: PMC7462306, DOI: 10.1158/1078-0432.ccr-18-2079.Peer-Reviewed Original ResearchConceptsResidual tumor volumeTumor cell killTissue sodium concentrationChemoradiation therapyOverall survivalHuman glioblastomaTumor volumeQuantitative sodium MR imagingCell killQuantitative sodium MRITumor cellsVariable tumor responseSodium MRITwo-compartment modelTumor resectionTumor responseDisease progressionSodium MR imagingTumor marginsMR imagingTherapyGlioblastomaTreatment volumeCancer cellsSodium concentration
2017
Dynamic contrast‐enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases
Hatzoglou V, Tisnado J, Mehta A, Peck KK, Daras M, Omuro AM, Beal K, Holodny AI. Dynamic contrast‐enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases. Cancer Medicine 2017, 6: 761-767. PMID: 28303695, PMCID: PMC5387174, DOI: 10.1002/cam4.1046.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesNSCLC brain metastasesLung cancer brain metastasesBrain metastasesCancer brain metastasesCell lung cancer brain metastasesDCE-MRIPrimary brain tumorsDifferent primary sitesImportant clinical implicationsMann-Whitney U testVolume transfer coefficientTumor histologyMultiple malignanciesMRI perfusionBrain tumorsMetastasisPrimary siteConventional MRIClinical implicationsPerfusion parametersTumor microvasculatureROC analysisU testPlasma volume
2016
“Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury”-Reply
Young RJ, Yang TJ, Hatzoglou V, Ulaner G, Omuro A. “Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury”-Reply. Neuro-Oncology 2016, 19: 301-302. PMID: 28040711, PMCID: PMC5464186, DOI: 10.1093/neuonc/now286.Peer-Reviewed Original ResearchPatterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial
Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-Oncology 2016, 19: 422-429. PMID: 27994065, PMCID: PMC5464299, DOI: 10.1093/neuonc/now238.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaProgression-free survivalOverall survivalCNS lymphomaPrognostic valueMRI characteristicsRandomized phase II trialEarly MRI evaluationFirst-line chemotherapyPatterns of relapsePhase II trialBaseline tumor sizeEnd of treatmentOverall tumor burdenPotential prognostic valueComplete response achievementHypersignal lesionsInfratentorial localizationProlonged OSII trialObjective responsePoor OSProspective trialMRI abnormalitiesTumor burdenDiagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma
Lin X, Lee M, Buck O, Woo K, Zhang Z, Hatzoglou V, Omuro A, Arevalo-Perez J, Thomas A, Huse J, Peck K, Holodny A, Young R. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma. American Journal Of Neuroradiology 2016, 38: 485-491. PMID: 27932505, PMCID: PMC5352508, DOI: 10.3174/ajnr.a5023.Peer-Reviewed Original ResearchSecond‐opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care
Hatzoglou V, Omuro AM, Haque S, Khakoo Y, Ganly I, Oh JH, Shukla-Dave A, Fatovic R, Gaal J, Holodny AI. Second‐opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care. Cancer 2016, 122: 2708-2714. PMID: 27219108, PMCID: PMC4992439, DOI: 10.1002/cncr.30083.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolDiagnostic ErrorsFemaleFollow-Up StudiesHumansImage Interpretation, Computer-AssistedInfantMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingNeoplasmsNeuroimagingObserver VariationPatient CarePhysiciansPrognosisRadiologistsReferral and ConsultationRetrospective StudiesTomography, X-Ray ComputedYoung AdultConceptsSecond-opinion interpretationsPatient managementMagnetic resonance imaging studySecond-opinion radiology reportsResonance imaging studyNational Cancer InstitutePatient ageNeuro-oncologistsCancer CenterDisease stageStudy criteriaCancer patientsClinical assessmentClinical impactNeck surgeonsRetrospective analysisHistopathologic analysisCancer InstituteImaging studiesRadiology reportsOutside reportsReference standardNeuroradiologistsSurgeonsDiscrepant reportsPrimary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control
Nguyen D, Houillier C, Choquet S, Cassoux N, Soussain C, Le Cossec C, Legarf-Tavernier M, Costopoulos M, LeHoang P, Bodaghi B, Omuro A, Hoang-Xuan K, Touitou V. Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control. Ophthalmology 2016, 123: 2047-2050. PMID: 27137876, DOI: 10.1016/j.ophtha.2016.03.043.Peer-Reviewed Original Research
2015
A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation
Hatzoglou V, Yang TJ, Omuro A, Gavrilovic I, Ulaner G, Rubel J, Schneider T, Woo KM, Zhang Z, Peck KK, Beal K, Young RJ. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro-Oncology 2015, 18: 873-880. PMID: 26688076, PMCID: PMC4864262, DOI: 10.1093/neuonc/nov301.Peer-Reviewed Original ResearchConceptsRadiation injuryPET-CTRadiation therapyProspective trialDCE-MRITumor progressionMaximum standardized uptake valueFluorine-18 fluorodeoxyglucose PET-CTFDG PET-CTDiagnosis of progressionNormal brain ratioFluorodeoxyglucose PET-CTStandardized uptake valueDynamic contrast-enhanced MRIWilcoxon rank sum testContrast-enhanced MRIBrain tumor progressionEffective imaging techniqueVolume transfer coefficientRank sum testCranial irradiationBrain ratioBrain malignanciesLesion outcomeBrain lesionsClinical Reasoning
Faivre G, Pentsova E, Demopoulos A, Taillibert S, Rosenblum M, Omuro A. Clinical Reasoning. Neurology 2015, 85: e57-e61. PMID: 26283762, PMCID: PMC4548283, DOI: 10.1212/wnl.0000000000001848.Peer-Reviewed Original ResearchAgedBrain NeoplasmsFatal OutcomeFemaleGlioblastomaHumansMagnetic Resonance ImagingMeningeal NeoplasmsDiffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
Prager A, Martinez N, Beal K, Omuro A, Zhang Z, Young R. Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence. American Journal Of Neuroradiology 2015, 36: 877-885. PMID: 25593202, PMCID: PMC4731220, DOI: 10.3174/ajnr.a4218.Peer-Reviewed Original ResearchConceptsTreatment-related changesRecurrent tumorsHigh-grade gliomasSurgical resectionRecurrent high-grade gliomaLow relative cerebral blood volumeSubanalysis of patientsUtility of DWIRelative cerebral blood volumeTreatment-related effectsCerebral blood volumeWilcoxon rank sum testConventional MR imagingRank sum testConsecutive patientsHistopathologic evidenceMass lesionDSC perfusionRadiation therapyBlood volumeGrade gliomasPatientsLow perfusionTumorsDSC maps
2014
Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. Clinical Cancer Research 2014, 20: 5023-5031. PMID: 25107913, PMCID: PMC4523080, DOI: 10.1158/1078-0432.ccr-14-0822.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiopsyBrain NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyDacarbazineFemaleGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedRadiosurgeryTemozolomideTreatment OutcomeYoung AdultConceptsObjective response rateOverall survivalRadiotherapy schedulesMedian overall survivalPhase II studyHypofractionated Stereotactic RadiotherapyPhase II trialApparent diffusion coefficient ratioRelative cerebral blood volumeDynamic susceptibility contrast perfusion MRICerebral blood volumeNeuropsychological test scoresMedian PFSPersistent hypermetabolismAdjuvant temozolomidePrimary endpointII studyII trialPoor OSStandard dosesFDG-PETPrognostic valuePoor prognosisHistorical controlsTumor volume
2013
Primary leptomeningeal lymphoma
Taylor JW, Flanagan EP, O'Neill BP, Siegal T, Omuro A, DeAngelis L, Baehring J, Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor T, Blay JY, Korfel A, Betensky RA, Lopes MB, Schiff D. Primary leptomeningeal lymphoma. Neurology 2013, 81: 1690-1696. PMID: 24107866, PMCID: PMC3812109, DOI: 10.1212/01.wnl.0000435302.02895.f3.Peer-Reviewed Original ResearchConceptsPrimary leptomeningeal lymphomaPrimary CNS lymphomaLeptomeningeal lymphomaCNS lymphomaLeptomeningeal enhancementCSF cytologyMedian Eastern Cooperative Oncology Group performance statusRare formEastern Cooperative Oncology Group performance statusInternational Primary CNS Lymphoma Collaborative GroupIntra-CSF chemotherapyMedian overall survivalFavorable clinical responseCases of lymphomaOptimal diagnostic evaluationGene rearrangement studiesB-cell lymphomaMultifocal symptomsSalvage treatmentSystemic chemotherapyClinical responseOverall survivalPerformance statusMedian ageSystemic involvementBevacizumab for acute neurologic deterioration in patients with glioblastoma
Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncology 2013, 2: 413-418. PMID: 25054664, PMCID: PMC6136096, DOI: 10.2217/cns.13.40.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabBrainBrain NeoplasmsGlioblastomaHumansInpatientsKarnofsky Performance StatusMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalQuality of LifeRetrospective StudiesSurvival AnalysisTreatment OutcomeYoung AdultConceptsNeurologic dysfunctionNeurologic deteriorationOutpatient treatmentGlioblastoma patientsAcute neurologic dysfunctionDose of bevacizumabAcute neurologic deteriorationSevere neurologic dysfunctionQuality of lifeBevacizumab treatmentHospitalized patientsRetrospective reviewSteroid dependenceDexamethasone administrationRehabilitation admissionTumor locationPeritumoral edemaBevacizumabPatientsAbstractTextDysfunctionTreatmentGlioblastomaHospitalizationEdemaPotential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma
Young R, Gupta A, Shah A, Graber J, Schweitzer A, Prager A, Shi W, Zhang Z, Huse J, Omuro A. Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma. American Journal Of Neuroradiology 2013, 34: 2271-2277. PMID: 23811973, PMCID: PMC4712068, DOI: 10.3174/ajnr.a3604.Peer-Reviewed Original ResearchAdolescentAdultAgedAged, 80 and overBiomarkers, TumorBrain NeoplasmsErbB ReceptorsFemaleGene AmplificationGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedMolecular ImagingPreoperative CarePrognosisReproducibility of ResultsSensitivity and SpecificityTissue DistributionUp-RegulationYoung Adult
2012
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma
Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A, Consortium F. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leukemia & Lymphoma 2012, 54: 58-61. PMID: 22656234, PMCID: PMC4802006, DOI: 10.3109/10428194.2012.698736.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaRecurrent primary central nervous system lymphomaCentral nervous system lymphomaNervous system lymphomaSystem lymphomaDay 1Prospective multicenter phase II trialMedian progression-free survivalMulticenter phase II studyMulticenter phase II trialAggressive salvage treatmentMedian overall survivalPhase II studyPhase II trialProgression-free survivalCycles of consolidationEvaluable patientsII trialSalvage treatmentII studyImmunocompetent patientsOverall survivalComplete responseRetrospective studyPatientsAtypical and anaplastic meningiomas treated with bevacizumab
Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. Journal Of Neuro-Oncology 2012, 109: 187-193. PMID: 22544653, DOI: 10.1007/s11060-012-0886-4.Peer-Reviewed Original ResearchConceptsProgression-free survivalVascular endothelial growth factor receptorAnaplastic meningiomasRadiographic responseMedian progression-free survivalBest radiographic responseEfficacy of bevacizumabMonths PFS rateEndothelial growth factor receptorKaplan-Meier statisticsActivity of bevacizumabEffective chemotherapeutic optionsAnti-angiogenic agentsTumor blood volumeMR perfusion studiesGrowth factor receptorPFS ratesStable diseaseBevacizumab therapyOverall survivalRANO criteriaRetrospective reviewSurgical optionsProspective studyAggressive tumors